TY  - GEN 
AU  - Sobas, M.
AU  - Knopinska-Posluszny, W.
AU  - Pi?tkowska-Jakubas, B.
AU  - García-Álvarez, F.
AU  - Díez, M.E.A.
AU  - Caballero, M.
AU  - Martínez-Cuadrón, D.
AU  - Aguiar, E.
AU  - González-Campos, J.
AU  - Garrido, A.
AU  - Algarra, L.
AU  - Salamero, O.
AU  - de la Serna, J.
AU  - Sayas, M.J.
AU  - Pérez Encinas, Manuel Mateo
AU  - Vives, S.
AU  - Vidriales, B.
AU  - Labrador, J.
AU  - Prado, A.I.
AU  - Celebrin, L.
AU  - Mayer, J.
AU  - Brioso, J.
AU  - de Laiglesia, A.
AU  - Bergua, J.M.
AU  - Amigo, M.L.
AU  - Rodriguez-Medina, C.
AU  - Polo, M.
AU  - Pluta, A.
AU  - Cichocka, E.
AU  - Skarupski, M.
AU  - Sanz, M.A.
AU  - Wierzbowska, A.
AU  - Montesinos, P.
PY  - 2024
SN  - 1432-0584
UR  - http://hdl.handle.net/20.500.11940/20390
AB  - The most important challenges in acute promyelocytic leukemia (APL) is preventing early death and reducing long-term events, such as second neoplasms (s-NPLs). We performed a retrospective analysis of 2670 unselected APL patients, treated with PETHEMA...
LA  - eng
KW  - Humans
KW  - Adult
KW  - Leukemia, Promyelocytic, Acute
KW  - Tretinoin
KW  - Neoplasms, Second Primary
KW  - Incidence
KW  - Retrospective Studies
KW  - Treatment Outcome
KW  - Risk Factors
KW  - Pathologic Complete Response
KW  - Antineoplastic Combined Chemotherapy Protocols
TI  - Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience
DO  - 10.1007/S00277-023-05582-Y
KW  - AS Santiago AP
KW  - CHUS
VL  - 103
ER  -